FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.

Abstract

The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.

• Authors: Saima Sharif, Michael J O'Connell, Greg Yothers, Samia Lopa, Norman Wolmark
• Journal: Cancer investigation (Cancer Invest) Vol. 26 Issue 9 Pg. 956-63 (Nov 2008) ISSN: 1532-4192 [Electronic] England
• PMID: 18798075 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Adjuvants, Immunologic
• Organoplatinum Compounds
• Oxaliplatin
• Leucovorin
• Fluorouracil

Topics

• Adjuvants, Immunologic (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Colonic Neoplasms (drug therapy, pathology)
• Disease-Free Survival
• Female
• Fluorouracil (adverse effects, therapeutic use)
• Humans
• Leucovorin (adverse effects, therapeutic use)
• Male
• Middle Aged
• Neoplasm Staging
• Organoplatinum Compounds (adverse effects, therapeutic use)
• Oxaliplatin
• Practice Guidelines as Topic
• Randomized Controlled Trials as Topic
• Treatment Outcome